{"url":"https://newsforagent.com/news/2026-11-06/zylox-tonbridge-gl-capital-lifetech-investment","markdown_url":"https://newsforagent.com/news/2026-11-06/zylox-tonbridge-gl-capital-lifetech-investment.md","title":"Zylox-Tonbridge Leads HK$1.482 Billion LifeTech Investment","headline":"Zylox-Tonbridge and GL Capital to Invest HK$1.482 Billion in LifeTech Scientific","description":"Zylox-Tonbridge and GL Capital will invest about HK$1.482 billion in LifeTech Scientific through Lighthouse Two.","section":"Funding","published_at":"2026-11-06T18:03:59+00:00","modified_at":"2026-11-06T18:03:59+00:00","author":"News Desk","key_takeaways":["Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific through GL Lighthouse Two Investment Limited.","Zylox-Tonbridge will hold a 60% stake in Lighthouse Two through an investment of approximately HK$889 million.","GL Capital will subscribe for 39.8 million new Zylox-Tonbridge shares at HK$22 per share, about 10.8% of the enlarged issued share capital."],"companies":[{"name":"Zylox-Tonbridge","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00kin7j/zylox-tonbridge","website":"https://www.zyloxtb.com"},{"name":"Lifetech Scientific Co, Ltd","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0037aa5/lifetech-scientific-co-ltd","website":"http://www.lifetechmed.com"},{"name":"GL Capital","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0000n48/gl-capital","website":"https://www.gl-investment.com"}],"source":{"publisher":"PR Newswire","title":"Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform","url":"https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932244.html"},"other_sources":[],"tags":["Funding","Zylox-Tonbridge","Lifetech Scientific Co, Ltd","GL Capital"],"body_markdown":"Zylox-Tonbridge Medical Technology and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific Corporation through GL Lighthouse Two Investment Limited, which will subscribe for newly issued shares representing approximately 16.7% of LifeTech's enlarged share capital, [PR Newswire](https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932244.html) reported on November 6, 2026.\n\n## How the Lighthouse Two Investment Is Structured\n\n[Zylox-Tonbridge](https://akta.pro/company-profiles/00kin7j/zylox-tonbridge) will hold a 60% stake in Lighthouse Two through an investment of approximately HK$889 million. Upon completion, Lighthouse Two will become [LifeTech](https://akta.pro/company-profiles/0037aa5/lifetech-scientific-co-ltd)'s largest single shareholder.\n\nIn a related transaction, [GL Capital](https://akta.pro/company-profiles/0000n48/gl-capital) will subscribe for 39.8 million newly issued Zylox-Tonbridge shares at HK$22 per share, representing approximately 10.8% of the company's enlarged issued share capital. The subscription price represents a 13.5% premium to the closing share price on the announcement date and a 15.4% premium to the average closing price over the preceding five trading days.\n\nThe proceeds will support Zylox-Tonbridge's potential future investments in LifeTech and international business development. Zylox-Tonbridge and GL Capital may acquire additional shares in LifeTech, and Zylox-Tonbridge intends to pursue a potential merger with LifeTech.\n\nDr. Jonathon Zhong Zhao, Chairman of Zylox-Tonbridge, said: \"This strategic investment marks an important milestone in our ambition to build a leading integrated vascular and structural heart intervention platform in China.\"\n\nLifeTech terminated a framework agreement on November 5, 2026, concerning the proposed acquisition of Starway equity and other matters, The future of trading reported.\n\n## Zylox-Tonbridge's Revenue and Profit Growth\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Zylox-Tonbridge reported full-year 2025 revenue of RMB 1.06 billion, up 35.1% year over year, and net profit of RMB 244 million, up 143.7% year over year. Non-IFRS adjusted net profit was RMB 273 million. International revenue surged 115.5% to RMB 48.65 million.\n\nThe same records show Zylox-Tonbridge entered into a definitive agreement in January 2026 to acquire Germany-based Optimed Medizinische Instrumente GmbH, a specialist in minimally invasive vascular and endourology devices founded in 1996 and based in Ettlingen, Germany.\n\n| Figure | Value |\n| --- | --- |\n| Full-year 2025 revenue | RMB 1.06 billion, up 35.1% year over year |\n| 2025 net profit | RMB 244 million, up 143.7% year over year |\n| Non-IFRS adjusted net profit | RMB 273 million |\n| International revenue | RMB 48.65 million, up 115.5% year over year |\n\n## LifeTech's Interim Results\n\nLifeTech Scientific Corporation reported unaudited interim results for the six months ended June 30, 2026, with revenue of about RMB600.8 million and a gross profit margin of 77.5%, up 3.9 percentage points, Aijourn reported.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}